Back

Hutchison China MediTech upgraded to Buy with $18.50 price target

  • Daiwa upgraded Hutchison China MediTech Limited to Buy after its GSK licensing deal.
  • Daiwa set a new price target of $18.50 for HCM.
  • GSK received exclusive commercialization rights to HCM’s experimental cancer therapy.

Hutchison China MediTech Limited (HCM) received a Buy rating upgrade from Daiwa, which set a new price target of $18.50 after a major licensing deal with GSK. The agreement gives GSK exclusive rights to commercialize HCM’s experimental cancer therapy.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Hutchison China MediTech upgraded to Buy with $18.50 price target - CoinPost Terminal